ABSTRACT
No disponible
Subject(s)
Head and Neck Neoplasms , Laryngeal Neoplasms , Nasopharyngeal NeoplasmsABSTRACT
We report in this paper a case of a tonsillar angiofibroma, whose histopathological features did not differ from its nasopharyngeal counterpart. In an exhaustive review done we have only found another one reference, in the german literature of such location.
Subject(s)
Angiofibroma/diagnosis , Tonsillar Neoplasms/diagnosis , Adult , Humans , MaleABSTRACT
BACKGROUND: Using chemotherapy as a part of each treatment fraction remains unexplored. This study integrates the concomitant administration of carboplatin with hyperfractionated irradiation by optimizing chemopotentiation through carboplatin administration with each irradiation fraction. METHODS: From February 1993 to August 1996, 52 patients with advanced head and neck cancer were treated on a twice-a-day chemoradiotherapy schedule. Each fraction consisted of 115 cGy preceded by 5 mg/m2 of carboplatin. Treatment was given 5 days a week up to total doses of 350 mg/m2 of carboplatin + 8050 cGy in 7 weeks. RESULTS: All (100%) of patients tolerated the treatment (83% as scheduled). Acute and late toxicities were moderate. Rates of 96% complete response (CR) and 4% partial response (PR) were achieved. At 52 months, local control and cause-specific survival rates are 72% and 59%, respectively. Nodal control rate is 95%. CONCLUSION: These results show potential for improvement upon hyperfractionated radiotherapy alone and compare favorably with those of most reported trials.
Subject(s)
Antineoplastic Agents/administration & dosage , Carboplatin/administration & dosage , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/radiotherapy , Dose Fractionation, Radiation , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/radiotherapy , Adult , Aged , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Combined Modality Therapy , Disease-Free Survival , Drug Administration Schedule , Female , Follow-Up Studies , Head and Neck Neoplasms/mortality , Head and Neck Neoplasms/pathology , Humans , Male , Middle Aged , Neoplasm Staging , Pilot Projects , Survival Rate , Treatment OutcomeABSTRACT
We studied four generations of a Canary Islands family presenting a tardive heredodegenerative hearing loss, associated with IgA mesangial glomerulonephritis, of probable autosomal dominant heredity. With respect to the family, we revised Alport's syndrome, for possible transmission associated with X chromosome, as well as heredodegenerative hearing loss associated with renal pathology of autosomic transmission currently described; we differentiate these hearing losses from our case study, and we discuss the pathogeny of the auditive affection in the said hereditary syndromes. Lastly, we stress the autoimmune hypothesis because of the IgA nephropathy association in the family case, and we list the characteristics of the syndrome described.
Subject(s)
Glomerulonephritis, IGA/genetics , Hearing Loss, Sensorineural/genetics , Adolescent , Adult , Diagnosis, Differential , Female , Genes, Dominant , Hearing Loss, Bilateral/genetics , Hearing Loss, Sensorineural/diagnosis , Humans , Male , Middle Aged , Nephritis, Hereditary/diagnosis , Pedigree , Spain , SyndromeABSTRACT
This is a new case of Esthesioneuroblastoma to joint the other 3 of our Archives. The opportunity is profited in order to make a revision on the subject.
